Investigational therapeutic restores microbiome diversity in recurrent C. difficile

Investigational therapeutic restores microbiome diversity in recurrent C. difficile

LAS VEGAS — CP101, an investigational microbiome therapeutic, restored microbiome diversity and prompted a sustained clinical cure among patients with recurrent Clostridioides difficile infection, according to a presentation.“Recurrent C. difficile infection is common following standard of care antibiotics and remains a significant burden on the health care system. Treatment guidelines recommend standard of care antibiotics; however, these therapies lead to significant microbiome disruptions which impairs colonization resistance,” Jessica R. Allegretti, MD, MPH, FACG, anRead More

Share on facebook
Share on twitter
Share on linkedin